Share chart Dynavax Technologies Corporation
Extended chart
Simple chart
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, биофармацевтическая компания, специализируется на разработке и коммерциализации новых вакцин в Соединенных Штатах. Компания продает HEPLISAV-B, вакцину против гепатита B для предотвращения инфекции, вызываемой всеми известными подтипами вируса гепатита B, в возрасте 18 лет и старше в Соединенных Штатах и Европе. Он также производит и продает CpG 1018, адъювант, используемый в HEPLISAV-B. Корпорация Dynavax Technologies заключила соглашение о сотрудничестве с Valneva Scotland Limited; соглашение с Serum Institute of India Pvt. Ltd . more detailsMain settings
| IPO date | 2004-02-19 |
|---|---|
| ISIN | US2681582019 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | link |
| Цена ао | 9.8 |
| Change price per day: | 0% (9.8) |
|---|---|
| Change price per week: | -0.3052% (9.83) |
| Change price per month: | -10.09% (10.9) |
| Change price per 3 month: | -26.97% (13.42) |
| Change price per half year: | -22.59% (12.66) |
| Change price per year: | -13.96% (11.39) |
| Change price per 3 year: | -19.14% (12.12) |
| Change price per 5 year: | +133.61% (4.195) |
| Change price per 10 year: | -56.68% (22.62) |
| Change price per year to date: | -23.62% (12.83) |
Grade
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| Blackrock Inc. | 23 | 17.72 |
| State Street Corporation | 11 | 8.11 |
| Vanguard Group Inc | 9 | 7.18 |
| Deep Track Capital, LP | 9 | 6.98 |
| Federated Hermes, Inc. | 8 | 6.1 |
| Chicago Capital, LLC | 6 | 4.31 |
| Kynam Capital Management, LP | 4 | 3.24 |
| Goldman Sachs Group Inc | 4 | 3.19 |
| Dimensional Fund Advisors LP | 4 | 3.1 |
| Geode Capital Management, LLC | 3 | 2.23 |
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Amplify Treatments Testing and Advancements ETF | 3.47 | 10.31 | 1.06 |
| Syntax Stratified SmallCap ETF | 0.17642 | 13.51 | 1.639 |
| Future Tech ETF | 0.14569 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.14569 | 618.5 | 0.8416 |
| iShares Morningstar Small-Cap Growth ETF | 0.03425 | 595.05 | 0.72598 |
| iShares Morningstar Small-Cap ETF | 0.03229 | 391.25 | 1.60498 |
| iShares Morningstar Small-Cap Value ETF | 0.02974 | 187.77 | 2.50476 |
| 0.58 | 320.39 | 1.32 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Ryan Spencer | CEO & Director | 1.25M | 1978 (47 years) |
| Mr. David F. Novack | President & COO | 925.6k | 1962 (63 years) |
| Ms. Kelly MacDonald | Senior VP & CFO | 674.27k | 1984 (41 year) |
| Mr. Justin Burgess | Chief Accounting Officer & Controller | N/A | |
| Mr. Jeff P. Coon | Senior VP & Chief Human Resources Officer | N/A | 1963 (62 years) |
| Mr. Donn Casale | Senior VP & Chief Commercial Officer | N/A | |
| Mr. Paul Cox | VP of Investor Relations & Corporate Communications | N/A | |
| Dr. Dong Yu | Senior Vice President of Vaccine Research | N/A | |
| Dr. Robert Janssen M.D. | Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs | 1954 (71 year) | |
| Mr. John L. Slebir | Senior VP & General Counsel | 1966 (59 years) |
About company
Address: United States, EmeryVille, 2100 Powell Street - Open in google maps, Open in yandex maps
Website: https://www.dynavax.com
Website: https://www.dynavax.com
